The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and...
Search results for - ANIXa
Anixa vaccines targeting unique mechanism in breast, ovarian cancer
Anixa Biosciences (NASDAQ:ANIX) is targeting a unique technology in two early-stage, first-in-class prophylactic cancer vaccines with the potential to prevent cancer cells from forming into breast and ovarian tumors.
Anixa Biosciences breast cancer vaccine featured in Daily Mail article
A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...
Anixa Biosciences receives Canadian patent for CAR-T cancer therapy technology
The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...
Anixa Biosciences in COVID-19 development pact with OntoChem
Anixa Biosciences (NASDAQ:ANIX) entered a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. “We believe that newly designed drugs that are purposefully developed...
Anixa Biosciences harnessing interactions between tumors and the immune system
Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...
Anixa Biosciences, Moffitt Cancer Center complete viral vector reformulation for CAR-T program
Anixa Biosciences (NASDAQ: ANIX) and the Moffitt Cancer Center, Anixa’s development partner, completed and validated the reformulation of the viral vector necessary for its CAR-T program. The purpose of the...
Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB
Ian Frazer Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to...
